期刊文献+

全脑放疗对脑转移瘤患者神经认知功能及生存质量的影响 被引量:1

下载PDF
导出
摘要 目的:探讨全脑放疗(WBRT)对脑转移瘤患者神经认知功能及生存质量的影响。方法:以2012年10月-2017年9月苏州九龙医院收治的行WBRT的脑转移瘤患者60例为观察对象,以简明精神状态量表(MMSE)为认知评估工具,阿尔茨海默病协作研究日常能力量表(ADCS-ADL)为生活质量评估工具。依照患者放疗前有无神经系统症状分为有症状组43例,无症状组17例。两组患者均接受为期3个月的随访,采用SPSS 20.0统计学软件,通过秩和检验和t检验评估放疗前后患者神经认知功能、生存质量及临床治疗效果。结果:无症状组与有症状组患者放疗后简明精神状态量表(MMSE)评分均明显高于本组基线水平,差异有统计学意义(P<0.05);无症状组放疗前后MMSE评分均明显高于有症状组,差异有统计学意义(P<0.05)。两组患者放疗前日常生活活动量表(ADCS-ADL)评分与放疗后对比,差异有统计学意义(P<0.05);两组间生活质量基线水平、放疗3个月后相比,差异无统计学意义(P>0.05);两组治疗总有效率对比,差异无统计学意义(P>0.05)。结论:WBRT能够改善BM患者的神经认知功能,约放疗后3个月最为明显,且放疗前有无神经系统症状对生活质量及治疗效果不产生较大影响。
作者 卢志娟 李超
出处 《中外医学研究》 2018年第35期45-47,共3页 CHINESE AND FOREIGN MEDICAL RESEARCH
  • 相关文献

参考文献3

二级参考文献21

  • 1温洪波,张振馨,牛富生,李凌.北京地区蒙特利尔认知量表的应用研究[J].中华内科杂志,2008,47(1):36-39. 被引量:353
  • 2Llovet JM, Ricci S, Mazzaferro V, et al. SHARP Investigators study group, sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4):378-390.
  • 3Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebocon- trolled trial[J]. Lancet Oncol, 2009, 10(1):25-34.
  • 4Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to eval- uate theresponse to treatment in solid tumors, european organiza- tion for research and treatment of cancer, national cancer institute of the united states, national cancer institute of canada[J]. J Nati Cancer Inst, 2000, 92(3):205-216.
  • 5Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evalua- tion criteriain solid tumours: Revised REClST guideline (version 1.1) [J]. Eur J Cancer, 2009, 45(2):228-227.
  • 6Bruix J, Sherman M, Llovet JM, et al. EASI. panel of experts on HCC european association for the study of the liver, clinical manage- ment ofhepatocellular carcinoma, conclusions of the barcelona- 2000 EASL conference[J]. J Hepatol, 2001, 35(3):421-430.
  • 7Riccardo L, Josep ML. Modified RECIST(mREClST) assessment for hepatocellular carcinoma[J]. Semin in Liver Dis, 2010, 30(1):52-60.
  • 8YozoSato, Hirokazu Watanabe. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcathe- ter arterialchemoembolization): RECIST (response evaluation crite- ria in solid tumors)version LI and mRECIST (modified RECIST): JIV- ROSG-O602[J]. Ups J Med Sci, 2013, 118(1):16-22.
  • 9Gavanier M, Ayav A, Sellal C, et al. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Al- ternative response criteria (Choi, european association for the study of the liver, and modified response evaluation criteria in sol- id tumor (mREClST)) versus REClST 1.1[J]. Eur J Radiol, 2016, 85(1): 103-112.
  • 10Dawson LA, McGinn C J, Normolle D, et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies[J]. J ClinOncol, 2000, 18(11):2210-2218.

共引文献91

同被引文献13

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部